Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nipocalimab + etanercept
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
**Nipocalimab + etanercept** is a combination therapy under investigation primarily for autoimmune conditions such as rheumatoid arthritis. Nipocalimab is a monoclonal antibody that acts as an inhibitor of the neonatal Fc receptor (FcRn), leading to a reduction in circulating IgG levels and modulation of pathogenic autoantibodies. Etanercept is a recombinant fusion protein that functions as a soluble tumor necrosis factor (TNF) receptor, blocking TNF-mediated inflammatory signaling. The combination has been studied to evaluate pharmacokinetic drug-drug interactions and efficacy, particularly to assess whether FcRn inhibition affects the exposure and effectiveness of anti-TNF agents like etanercept[1][3][4][6].
- Other names
- nipocalimab + etanercept
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on nipocalimab + etanercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nipocalimab + etanercept.